Combination heart device reduced heart failure

September 1, 2009 By MARIA CHENG , AP Medical Writer

(AP) -- A two-in-one heart device to fix irregular beats and contraction patterns cut patients' chances of developing heart failure by 41 percent, new research says.

While the device spared many patients from going to the hospital, it made no difference in saving lives, and some doctors say they won't rush to implant more patients with the pricey devices.

The study compared patients who got a to correct abnormal heart rhythms with patients who got a device that added a heart resynchronization device, which helps the lower chambers of the at the same time.

The results were announced Tuesday at the European Society for Cardiology meeting in Barcelona and published online in the .

The defibrillator and resynchronization devices are commonly used in patients with serious , and doctors wondered if patients with mild illness might benefit.

"The answer is a clear, unequivocal yes," said Arthur Moss, of the University of Rochester Medical Center in New York, and the study's lead author.

Not everyone agreed. Douglas Zipes of the Indiana School of Medicine and a past president of the American College of Cardiology said too many patients were already getting the devices and that doctors needed to rethink who should get them.

Moss' study tracked more than 1,800 patients with mild heart disease in North America and Europe for more than four years. About half of the patients got a defibrillator, while the other half got a defibrillator plus a resynchronization device. The two implants are nearly identical, except the resynchronization device has an extra electrode that stimulates the left side of the heart.

Overall, patients who got the combined device had a 41 percent lower chance of developing heart failure, though women's chances dropped by 63 percent. The death rate in both device groups was about the same, around 3 percent.

The study was paid for by Boston Scientific Corp., which makes the devices.

In the U.S., about 60,000 patients with severe heart disease get the devices every year, out of more than 5 million people who have heart failure.

Some doctors thought the device's price - it sells for approximately $30,000 to $40,000, not including the cost of implantation - would be a major stumbling block to its acceptance. Patients with mild heart failure, who were not experiencing any painful symptoms, might also be reluctant to have surgery to get the device.

Clyde Yancy, president of the American Heart Association called it an "incremental (improvement), not a breakthrough." Yancy was not linked to the research.

Others agreed the study wouldn't immediately affect how heart failure patients are treated.

"Previous devices have shown us that it takes time to consider benefits for real-world populations," said Alfred Bove, president of the American College of Cardiology in a statement. "Even if costs were not a factor, we still do not have enough information to expand treatment right away."

On the Net:

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Related Stories

Recommended for you

Researchers illustrate how muscle growth inhibitor is activated, could aid in treating ALS

January 19, 2018
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for ...

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.